Afobazole Modulates Microglial Function via Activation of Both σ-1 and σ-2 Receptors

Javier Cuevas, Álex Rodríguez, Adam A. Behensky, Chris KatnikJournal of Pharmacology and Experimental Therapeutics 2011 · DOI

TL;DR

This study reveals that afobazole, an anxiolytic drug, acts on sigma-1 and sigma-2 receptors in microglia to inhibit their inflammatory responses, specifically migration and calcium signaling triggered by ATP and UTP. Furthermore, afobazole demonstrates significant cytoprotective effects, reducing microglial cell death during and after ischemic events, suggesting its potential as a therapeutic agent for neuroinflammatory diseases like stroke.

What Problem Does This Paper Address?

Microglia, the brain's resident immune cells, play a dual role in neuroinflammatory diseases such as ischemic stroke. While they can contribute to neuronal damage by releasing inflammatory mediators, they also possess neuroprotective functions. Understanding how to modulate microglial activity to favor their beneficial roles and suppress their detrimental ones is crucial for developing effective treatments. ATP is a key signaling molecule that activates microglia, prompting them to migrate to injury sites. However, the specific receptors involved in afobazole's effects on microglia and its potential to protect these cells from ischemic injury remained largely unexplored. This paper aims to elucidate the molecular mechanisms by which afobazole influences microglial function and survival, particularly in the context of purinergic receptor activation and ischemic stress.

Methods

The researchers employed a multi-pronged approach to investigate afobazole's effects on primary microglial cultures:

  • Migration Assays: A standard 48-well microchemotaxis chamber was used to quantify microglial migration in response to chemoattractants like ATP and UTP. This involved labeling cell nuclei with DAPI and counting migrated cells.
  • Calcium Imaging: Fura-2, a fluorescent indicator, was used to measure intracellular calcium ([Ca²⁺]ᵢ) elevations in response to ATP and UTP. This technique allowed for real-time monitoring of cellular responses.
  • Electrophysiology: Whole-cell patch-clamp electrophysiology was utilized to record membrane currents in response to ATP application. This method specifically investigated the role of sigma receptors in modulating ionotropic purinergic receptors (P2X channels).
  • Pharmacological Interventions: A range of sigma receptor ligands were employed:
  • Pan-selective antagonist: Metaphit was used to block all sigma receptor activity.
  • Sigma-1 selective antagonists: BD 1063, BD 1047, and NE-100 were used to specifically target sigma-1 receptors.
  • Sigma-2 selective antagonists: SM-21 and rimcazole were used to target sigma-2 receptors.
  • Sigma receptor agonist: DTG was used as a positive control for sigma receptor activation.
  • In Vitro Ischemia Model: Microglial cells were subjected to oxygen-glucose deprivation and azide treatment to mimic ischemic conditions. Cell death was quantified using a lactate dehydrogenase (LDH) cytotoxicity assay. The timing of afobazole application (during or after ischemia) was also investigated.

Datasets

Not discussed in the paper. The study utilized primary microglial cultures derived from Sprague-Dawley rat pups.

Key Insights and Ideas

  • Afobazole as a Pan-Sigma Agonist: The study strongly suggests that afobazole acts as a pan-sigma receptor agonist, meaning it activates both sigma-1 and sigma-2 receptor subtypes. This is supported by the fact that a pan-selective sigma antagonist (metaphit) blocked afobazole's effects, and subtype-selective antagonists partially reversed them.
  • Inhibition of Microglial Migration: Afobazole effectively inhibits microglial migration in response to ATP and UTP, key chemoattractants in neuroinflammation. This effect is concentration-dependent and mediated through sigma receptors.
  • Modulation of Purinergic Receptor Signaling: Afobazole's inhibition of microglial migration is linked to its ability to suppress intracellular calcium ([Ca²⁺]ᵢ) elevations and membrane currents induced by ATP and UTP. This indicates that afobazole interferes with the signaling pathways downstream of P2X and P2Y purinergic receptors.
  • Cytoprotection Against Ischemia: A significant finding is afobazole's ability to protect microglia from cell death induced by in vitro ischemia. This protective effect is observed even when afobazole is administered after the ischemic insult, highlighting its therapeutic potential for post-stroke recovery.
  • Dual Role of Sigma Receptors: The research underscores the critical role of both sigma-1 and sigma-2 receptors in mediating afobazole's effects on microglial migration and calcium signaling.

Key Results

  • Afobazole inhibited microglial migration in response to ATP and UTP in a concentration-dependent manner.
  • Preincubation with the sigma receptor antagonist metaphit significantly reduced afobazole's inhibitory effect on migration.
  • Sigma-1 selective antagonists (BD 1063, BD 1047, NE-100) partially blocked afobazole's inhibition of ATP-evoked migration, reducing the inhibition by ≥47%.
  • Sigma-2 selective antagonists (SM-21, rimcazole) also significantly lessened afobazole's inhibition of ATP-evoked migration, reducing it by 44-31%.
  • Afobazole and DTG significantly reduced ATP-evoked intracellular calcium ([Ca²⁺]ᵢ) elevations, with afobazole decreasing peak elevations by 81 ± 2%.
  • Afobazole inhibited ATP-evoked membrane currents by approximately 50%, suggesting an effect on P2X channels.
  • Metaphit preincubation diminished afobazole's inhibitory effects on both ATP- and UTP-evoked [Ca²⁺]ᵢ increases.
  • Afobazole significantly decreased microglial cell death during and after in vitro ischemia, with 100 µM afobazole reducing net cell death by over 50%.
  • Delayed application of afobazole (after the ischemic episode) still provided significant cytoprotection.

Limitations and Future Work

  • In Vitro Model: The study primarily uses in vitro models. While informative, future work should validate these findings in in vivo models of neuroinflammation and stroke to assess therapeutic efficacy and potential side effects in a more complex biological system.
  • Specific Receptor Subtypes: While the study implicates both sigma-1 and sigma-2 receptors, further research could pinpoint the precise contribution of each subtype and their downstream signaling pathways in mediating afobazole's effects.
  • Clinical Translation: Afobazole is already an approved drug in Russia for anxiety. However, its efficacy and safety for treating neuroinflammatory conditions like stroke in humans would require extensive clinical trials.
  • Mechanism of Cytoprotection: While afobazole demonstrates cytoprotection, the exact molecular mechanisms underlying this effect (e.g., anti-apoptotic pathways, antioxidant properties) warrant further investigation.
  • Interaction with Other Neurotransmitters/Receptors: The study focuses on purinergic receptors. Exploring how afobazole's sigma receptor modulation interacts with other neurotransmitter systems relevant to neuroinflammation and stroke could provide a more comprehensive understanding.

Summary updated

BibTeX
@article{cuevas2011afobazole,
  author = {Javier Cuevas and Álex Rodríguez and Adam A. Behensky and Chris Katnik},
  title = {{Afobazole Modulates Microglial Function via Activation of Both σ-1 and σ-2 Receptors}},
  journal = {Journal of Pharmacology and Experimental Therapeutics},
  year = {2011},
  doi = {10.1124/jpet.111.182816},
}
Figure